Farmasiet, Norway's largest online pharmacy, signs Agillic for advanced customer engagement
The Norwegian online pharmacy, Farmasiet, signs Agillic for advanced customer engagement to explore untapped business potential.
Farmasiet is Norway's largest online pharmacy, delivering thousands of both prescription drugs, non-prescription drugs and commodities throughout Norway and with pharmacists available online for fast and convenient expert advice.
Confident about the business value and potential of more advanced customer engagement, Farmasiet concluded they would need a new platform to deliver on their ambitions. The search was largely influenced by two key criteria: the technology should enable their advanced ideas, and they would need a European solution to ensure full compliance on data privacy and security.
Farmasiet decided on Agillic and in just six weeks, they launched a tailored solution including eCommerce integration, advanced customer journeys, product feeds, mobile optimisation, and more.
Hilde Andersen-Gott, CTO at Farmasiet, explains the choice of Agillic: 'We are convinced there is an untapped business potential and essentially chose Agillic because the platform enables us to execute on our ideas and capitalise on that potential – now and as we scale our ambitions further. Compliance was a given and with Agillic's flexibility, 'tailored' did not mean compromising on time to market.'
Christian Samsø, CEO at Agillic, adds: 'We are quite proud of welcoming Farmasiet. They had set a high bar for how a platform should empower their ideas to deliver on the business potential, and our platform checked all the boxes from compliance to the ability to scale customer journeys.'
For further information, please contact
Christian Samsøe, CEO
+45 24 88 24 24
[email protected]
About Agillic A/S
Agillic A/S (Nasdaq First North Growth Market Copenhagen: AGILC) is a Danish software company offering brands a platform through which they can work with data-driven insights and content to create, automate, and send personalised communication to millions. Agillic is headquartered in Copenhagen, Denmark. For further information, please visit agillic.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a minute ago
- Yahoo
Global markets face shaky week ahead as US pressure mounts on Ukraine
By Naomi Rovnick and Dhara Ranasinghe LONDON (Reuters) -Defence stocks and energy markets are likely to be in focus this week, as European leaders rushed to back Ukraine in talks with U.S. President Donald Trump that may pressure Kyiv to accept a peace deal favouring Russia. Investors are watching for signs that the U.S. may move closer to Russia in a bid to exploit vast, untapped Arctic energy resources, in a major geopolitical shift that piles pressure on Europe to rapidly boost defence spending. Trump and Russian President Vladimir Putin ended their weekend summit in Alaska without securing a Ukraine ceasefire agreement, with the U.S. President then saying he now wanted a rapid peace deal that Kyiv should accept. Ukrainian President Volodymyr Zelenskiy is travelling to Washington on Monday for talks that leaders of nations including Germany, the UK and France will now join. "Trump seems inclined to reduce or even end US support for Ukraine. Putin got him interested in business deals," Berenberg Chief Economist Holger Schmieding said in a note to clients. "As a result, the US may lift its sanctions on Russia and invest in Russia instead," he added. "Europe will have to spend a lot more for its own defence." DEFENCE STOCK RALLY Investors have bet on that outcome since February 2022, driving a supercharged rally in European aerospace and defence stocks with gains of over 600% for Leonardo and 1,500% for Germany's Rheinmetall. The euro has rallied 13% against the dollar this year and traded at about $1.17 on Friday. Bank of America strategist Michael Hartnett highlighted the potential for U.S.-Russia Arctic drilling projects to exploit 15% of the world's undiscovered oil and 30% of the world's undiscovered natural gas, resulting in a deep energy bear market. Brent crude, which dropped more than 1% to near $66 a barrel, on Friday, was still priced for a Ukraine peace deal, Hartnett cautioned, while Trump wanted lower energy prices for U.S. consumers. Ukraine's government bonds - key mood indicators - rallied when news of the summit emerged earlier this month but have stalled at a still-distressed 55 cents per dollar. "I would think they will be a bit weaker following the recent strength as the mood seems to favour Russia following Friday's summit," Aegon Asset Management head of emerging market debt Jeff Grills said. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
31 minutes ago
- Yahoo
What Nottingham Forest need to complete Douglas Luiz deal with Juventus
Recent reports claim that Nottingham Forest have an agreement on personal terms with midfielder Douglas Luiz, but the Premier League side still need to increase their offer to Juventus in order to close the deal. Juventus are looking to offload Douglas Luiz just one year on from his €50m arrival from Aston Villa, following what has been an underwhelming start to life in Italy for the Brazilian, which included just three Serie A starts in 2024-25. Several Premier League sides have expressed an interest in signing the Brazilian this window, but Football Italia understands that Nottingham Forest have been leading the race for several weeks. Forest have Douglas Luiz agreement, but no Juventus deal LEWISBURG, WEST VIRGINIA – JUNE 14: Douglas Luiz #26 of Juventus arrives at the airport prior to the official FIFA Club World Cup 2025 on June 14, 2025 in Lewisburg, West Virginia. (Photo by) According to recent updates from Fabrizio Romano and Forest have an agreement in place over a long-term contract with Douglas Luiz himself, but have not yet settled the deal with Juventus. Forest's opening offer reportedly stood at €30m, which the Bianconeri deemed too low. Calciomercato explains that Juventus require a fee in the region of €39m if they are to avoid making a capital loss on Douglas Luiz after only one year, given the €50m fee they spent last summer. Sunday's report suggests that an increase of a couple of million from Forest's original offer with the inclusion of performance-related bonuses, some easily achievable, could be enough to convince Juventus into selling.
Yahoo
an hour ago
- Yahoo
1 Stock Down 40% This Year to Buy and Hold
Key Points Novo Nordisk's shares have been trending downward due to clinical setbacks and underwhelming results. However, the company has some potential catalysts on the way that could jolt its stock price. Novo Nordisk looks attractive given its lineup and pipeline, especially at current levels. 10 stocks we like better than Novo Nordisk › Novo Nordisk (NYSE: NVO) first earned U.S. approval for its now-famous weight management medicine Wegovy in June 2021. That marked the beginning of a strong run for the company on the stock market. However, the Denmark-based drugmaker has given up most of these gains over the past year; the stock is down by 40% since January alone. Despite its recent misfortunes, Novo Nordisk's shares could still deliver strong returns to patient investors. Here's why. The weight management opportunity Novo Nordisk primarily develops medicines for diabetes and, in recent years, weight management. Its stock has plunged over the past year because its financial results haven't been as impressive as the market had hoped. It also faced some clinical setbacks, while its biggest rival in its core markets, Eli Lilly, earned some important wins. However, there's more to the story. The market for anti-obesity medications could grow at an incredibly rapid rate. Some analysts estimate that it will be worth $150 billion by 2035, compared to $15 billion last year. Novo Nordisk still has one of the deepest pipelines in the industry. In fact, it's challenging to find a company other than Eli Lilly that has more promising products. Recently, Novo Nordisk expanded its pipeline through various licensing deals. Here's one more thing that recently broke its way: Eli Lilly's oral GLP-1 candidate, orforglipron, did not perform nearly as well as expected in a phase 3 study. This opens the door for Novo Nordisk to catch up to its longtime rival. The company's oral version of Wegovy is currently awaiting approval from regulators in the U.S. The oral version led to an average weight reduction of 13.6% in a phase 3 clinical trial, slightly higher than the 12.4% that orforglipron recently posted in its late-stage study. While it's always hard to compare across clinical trials, the data at the very least suggests that oral Wegovy is comparable to orforglipron -- but only the former drug is closing in on approval. Novo Nordisk also has yet another promising anti-obesity candidate in phase 3 studies, amycretin, which the Denmark-based pharmaceutical giant is testing in both subcutaneous and oral formulations. Why is the race to develop an oral weight loss option so important? Pills are easier and cheaper to manufacture, store, and transport. So, compared to injectable weight loss therapies, oral versions would allow drugmakers to produce them more cost-effectively and to expand the reach of weight loss therapies. On top of that, some patients are strongly averse to needles. Because the current leading weight management drugs are administered subcutaneously, an oral option would likely take a decent share of the market. Novo Nordisk is likely to be first to market. And the company could follow up that win with another oral product in amycretin. The price is right Let's go back to Novo Nordisk's recent and disappointing financial results. In the first half of the year, revenue rose by 16% year over year to 154.9 billion Danish kroner ($24.2 billion), while net profit came in at 55.5 billion DKK ($8.7 billion). Perhaps that's not quite what the market expected to see, but these are still excellent results for a pharmaceutical giant -- most drugmakers of that size would be happy to grow their revenue at high-single-digit or low-double-digit rates. Meanwhile, the stock appears reasonably valued, trading at 13 times forward earnings, compared to the healthcare industry's average of 16.2. What's the verdict? Novo Nordisk looks attractive at current levels, given the company's strong pipeline in weight management and a lineup that continues to deliver consistent profits. Despite recent setbacks, the stock is well-positioned to deliver excellent results over the long term. Should you invest $1,000 in Novo Nordisk right now? Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Prosper Junior Bakiny has positions in Eli Lilly and Novo Nordisk. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. 1 Stock Down 40% This Year to Buy and Hold was originally published by The Motley Fool Sign in to access your portfolio
